Ventana vs. Vision Systems
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical Systems escalates its ongoing patent dispute with acquisition target Vision Systems and declines opportunity to increase its $346 mil. purchase offer after the latter firm's receipt of rival $374 mil. bid from Cytyc (1"The Gray Sheet" Sept. 18, 2006, p. 6). Ventana is keeping its options open, however, and could increase its offer later, noting it "reserves its right to take any other action, at any time, that it deems appropriate in connection with its transaction with Vision." The fresh lawsuit, filed Sept. 18 in Massachusetts federal court, alleges that Vision's Bond X and Bond Max automated tissue sample staining instruments infringe Ventana's '537 patent for "scheduling algorithms which enable optimal sequencing of multiple tests." Prior Ventana litigation alleging infringement of the firm's '861 dual bar code patent is ongoing. Cytyc says the new lawsuit will "not impede" its purchase plan...
You may also be interested in...
Cytyc’s Higher Bid For Vision Systems Puts Ball Back In Ventana’s Court
Cytyc's proposed $374 mil. offer for cancer and infectious disease detection equipment maker Vision Systems Sept. 13 could start a bidding war for the Australian company
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.